Tovikkai Chutwichai, Charman Susan C, Praseedom Raaj K, Gimson Alexander E, van der Meulen Jan
Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK Department of Surgery, University of Cambridge, Cambridge, UK.
Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
BMJ Open. 2015 May 14;5(5):e006971. doi: 10.1136/bmjopen-2014-006971.
We assessed the impact of comorbidity on mortality in three periods after liver transplantation (first 90 days, 90 days-5 years and 5-10 years).
Prospective cohort study using records from the UK Liver Transplant Audit (UKLTA) linked to Hospital Episode Statistics (HES), an administrative database of hospital admissions in the English National Health Service (NHS). Comorbidities relevant for liver transplantation were identified from the 10th revision of the International Classification of Diseases (ICD-10) codes in HES records of admissions in the year preceding their operation. Multivariable Cox regression was used to estimate HRs for three different time periods after liver transplantation.
All liver transplant centres in the NHS hospitals in England.
Adults who received a first elective liver transplant between April 1997 and March 2010 in the linked UKLTA-HES database.
Patient mortality in three different time periods after transplantation.
Among 3837 recipients, 45.1% had comorbidities. Recipients with cardiovascular disease had statistically significantly higher mortality in all three periods after transplantation (first 90 days: HR=2.0; 95% CI 1.4 to 2.9, 90 days-5 years: 1.6; 1.2 to 2.2, beyond 5 years: 2.8; 1.7 to 4.4). Prior congestive cardiac failure (3.2; 2.1 to 4.9) significantly increased mortality only in the first 90 days. History of non-hepatic malignancy appeared to increase risk over all periods, but significantly only in the first 90 days (1.9; 1.0 to 3.6). A diagnosis of connective tissue disease, dementia, diabetes, chronic pulmonary and renal disease did not have a significant impact on mortality in any period.
The impact of comorbidities present at the time of transplantation changes with time after transplantation. Renal disease, pulmonary disease and diabetes had no impact on mortality in contrast to previous reports.
我们评估了合并症对肝移植后三个时期(前90天、90天至5年以及5至10年)死亡率的影响。
前瞻性队列研究,使用英国肝移植审计(UKLTA)与医院事件统计(HES)相链接的记录,HES是英国国家医疗服务体系(NHS)中医院入院情况的行政数据库。在患者手术前一年的HES入院记录中,根据国际疾病分类第10版(ICD - 10)编码确定与肝移植相关的合并症。采用多变量Cox回归来估计肝移植后三个不同时间段的风险比(HRs)。
英格兰NHS医院中的所有肝移植中心。
1997年4月至2010年3月期间在链接的UKLTA - HES数据库中接受首次择期肝移植的成年人。
移植后三个不同时间段的患者死亡率。
在3837名接受者中,45.1%患有合并症。患有心血管疾病的接受者在移植后的所有三个时期死亡率均有统计学显著升高(前90天:HR = 2.0;95%置信区间1.4至2.9,90天至5年:1.6;1.2至2.2,5年以后:2.8;1.7至4.4)。既往充血性心力衰竭(3.2;2.1至4.9)仅在前90天显著增加死亡率。非肝恶性肿瘤病史似乎在所有时期都增加风险,但仅在前90天显著(1.9;1.0至3.6)。结缔组织病、痴呆、糖尿病、慢性肺病和肾病的诊断在任何时期对死亡率均无显著影响。
移植时存在的合并症的影响随移植后的时间而变化。与先前报告相反,肾病、肺病和糖尿病对死亡率无影响。